Navigation Links
Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
Date:6/24/2008

SOUTH SAN FRANCISCO, Calif., June 24 /PRNewswire/ -- Portola Pharmaceuticals, a clinical-stage biopharmaceutical developing best-in-class therapeutics for acute and chronic cardiovascular and inflammatory diseases, today announced that Bill Lis has joined the company as Vice President of Business and Commercial Development. Mr. Lis will be responsible for the company's corporate partnering activities as well as commercial strategy for Portola's portfolio of clinical and preclinical programs. He will join the company's executive management team.

Mr. Lis has over 17 years of experience in biopharmaceutical and medical device sales & marketing, medical affairs, and business development. From 2005 until 2008 he was Vice President, Business and New Product Development, Scios, Inc. (A Johnson and Johnson Company) where, most recently, he was responsible for cardiovascular business licensing strategies and activities and commercial operations. He led successful in-licensing activities and pre-market and commercial infrastructure development for Xarelto(R) (rivaroxaban) a Phase III drug candidate, filed for EMEA regulatory approval. Prior to joining Scios, he was Director of Marketing and New Products, Millennium Pharmaceuticals, Inc. where he held positions of increasing leadership, including the management of marketing activities for Integrilin(R) (eptifibatide), a best in class antithrombotic drug. Previously, at Rhone Poulenc Rorer and Ethicon Endo Surgery he was involved in the launch and commercialization of several products, including Lovenox(R) (enoxaparin). He holds a B.S. in Finance from the University of Maryland.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular disease. Portola has two antithrombotic drug candidates in Phase II clinical development. Portola's lead compound, betrixaban (PRT054021), is an oral Factor Xa inhibitor with target markets that include the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction (MI) and stroke. Portola's other clinical compound, PRT060128, is an oral and intravenous ADP receptor antagonist being developed for patients with acute coronary syndrome, for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention and for secondary prevention of MI and stroke. In addition, Portola has a robust preclinical pipeline targeting opportunities in thrombosis and hemostasis as well as in cancer and inflammatory diseases.


'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... ... 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), a ... webinar on Performing Quality Investigations: Getting to Root Cause. This ... charge. , Incomplete investigations are still a major concern to the Regulatory Authorities ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):